Outcome of the Meeting of the Board of Directors held on September 03, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To, Date: 03/09/2026 The Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Subject: Outcome of the Meeting of the Board of Directors held on September 03, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Kimia Biosciences Limited at its meeting held on Thursday, September 03, 2026, commenced at 4:30 P.M. and concluded at 5:30 P.M., and inter alia considered and approved / took note of the following matters: 1. Re-appointment of Mr. Sameer Goel (DIN: 00161786) as Director, liable to retire by rotation, subject to approval of the Members at the ensuing 33rd Annual General Meeting ("AGM") Annexure A. 2. Appointment of Mr. Amulya Kumar Nayak (DIN: 11667557) as Non-Executive Director, liable to retire by rotation, subject to approval of the Members at the ensuing AGM Annexure B. 3. Appointment of Ms. Reema Goyal (DIN: 11266730) as Non-Executive Independent Woman Director for a term of five consecutive years commencing from April 04, 2026 to April 03, 2031, subject to approval of the Members Annexure C. 4. Appointment of Mr. Avinash Prabhat (DIN: 10997441) as Non-Executive Independent Director for a term of five consecutive years commencing from April 04, 2026 to April 03, 2031, subject to approval of the Members Annexure D. 5. Considered and approved the remuneration payable to M/s Mahesh Singh & Co., Cost Accountants (FRN: 100441), appointed as Cost Auditors of the Company, and approved the proposal for obtaining members’ approval / ratification at the ensuing AGM for remuneration of ₹40,000/- plus applicable out-of-pocket expenses. 6. Took note of the Cost Audit Report for the Financial Year 2025-26 submitted by the Cost Auditor of the Company and placed the same on record. 7. Approved the proposal for seeking approval of the Members for increasing the borrowing limits of the Company under Section 180(1)(c) of the Companies Act, 2013, to the extent and on the terms to be set out in the Notice of the ensuing AGM. 8. Approved the proposal for seeking approval of the Members for creation of mortgage and/or charge on all or any of the movable and/or immovable properties of the Company, to secure the borrowings of the Company, on the terms to be set out in the Notice of the ensuing AGM. compliance.kimiabiosciences@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.:L24239HR1993PLC032120 9. Approved the proposal for seeking approval of the Members for making loans, giving guarantees and/or providing securities in connection with loans, in accordance with Section 185 and other applicable provisions of the Companies Act, 2013, as may be required. 10. Approved the proposal for seeking approval of the Members for increasing the limits applicable for making investments, extending loans, giving guarantees and/or providing securities in connection with loans to any person or body corporate, in accordance with Section 186 and other applicable provisions of the Companies Act, 2013. 11. Took on record the Secretarial Audit Report for the Financial Year 2025-26 provided by M/s Maya Sharma & Associates, Company Secretaries; 12. Considered and approved the appointment of Ms. Maya Sharma, Company Secretary in Practice, as the Scrutinizer for the ensuing 33rd AGM. 13. Approved the Notice of the 33rd AGM of the Members of the Company, scheduled to be held on Monday, September 28, 2026 at the Registered Office of the Company, together with the Explanatory Statement and other relevant annexures thereto. 14. Considered and approved the Board’s Report along with its annexures and the 33rd Annual Report of the Company for the Financial Year 2025-26, for circulation to the Members of the Company. 15. Fixed the Important Dates for the purpose of ensuing Annual General Meeting of the Company: Cut off date for e-voting : September 21, 2026 E-voting Start Date & time : September 25, 2026 (9:00 A.M.) E-voting End Date & time : September 27, 2026 (5:00 P.M.) The disclosures/details required under Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and the SEBI Master Circular referred to above in respect of the changes in Directors are enclosed as Annexures A to D to this letter. Kindly take the above information on record. Thanking you, Yours faithfully, For Kimia Biosciences Limited Abhishek Kumar Pandey (Company Secretary and Compliance Officer) M. No. F12457 Date: 03/09/2026 Place: New Delhi Encl.: As above. compliance.kimiabiosciences@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.:L24239HR1993PLC032120 ANNEXURE A RE-APPOINTMENT OF MR. SAMEER GOEL Disclosure under Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Particulars / Disclosure Requirement Details Name of Director Mr. Sameer Goel (DIN: 00161786) Reason for change Re-appointment as Director of the Company, liable to retire by rotation, subject to approval of the Members at the ensuing 33rd AGM. Date of appointment / re-appointment Subject to approval of the Members at the ensuing 33rd AGM. His re-appointment as Managing Director for a further term of five years commencing from March 29, 2026 to March 28, 2031 was earlier approved by the Members; the Board has now placed his continuation as a Director liable to retire by rotation before the Members. Term of appointment / re-appointment As Director, liable to retire by rotation, in accordance with the applicable provisions of the Companies Act, 2013 and the Articles of Association of the Company. Brief profile Mr. Sameer Goel is a Delhi University Commerce graduate and has extensive experience in the Indian pharmaceutical/API sector, with expertise in business development, product development, strategic marketing and operations management. He is a founder of Kimia Biosciences Limited and has substantial experience in the pharmaceutical APIs business. Disclosure of relationship between Mr. Sameer Goel is not related to any of the Directors Directors of the Company. Information as required under BSE Mr. Sameer Goel is not debarred from Circular No. LIST/COMP/14/2018-19 holding the office of Director by virtue of any dated June 20, 2018 order passed by SEBI or any other such authority. compliance.kimiabiosciences@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.:L24239HR1993PLC032120 ANNEXURE B APPOINTMENT OF MR. AMULYA KUMAR NAYAK Disclosure under Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Particulars / Disclosure Requirement Details Name of Director Mr. Amulya Kumar Nayak (DIN: 11667557) Reason for change Appointment as Non-Executive, Non- Independent Director of the Company, liable to retire by rotation, subject to approval of the Members at the ensuing 33rd AGM. Date of appointment April 18, 2026 (appointment as Additional Director); the matter is now placed before the Members for approval / regularisation as Director. Term of appointment As Director, liable to retire by rotation, subject to approval of the Members at the ensuing 33rd AGM. Brief profile Mr. Amulya Kumar Nayak is a seasoned finance and accounts professional with more than 32 years of experience in finance, accounts, taxation, audit, MIS, budgeting, banking and commercial functions. He has worked with reputed organisations including Punj Lloyd Ltd., GTL Ltd., Pepsi Foods Ltd. and Sterling Holiday Resorts, and pos [Showing first 8,000 characters — download PDF for full document]